Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Schey, Steve; Brown, Sarah R; Tillotson, Avie-Lee; Yong, Kwee; Williams, Cathy; Davies, Faith; Morgan, Gareth; Cavenagh, Jamie; Cook, Gordon; Cook, Mark; Orti, Guillermo; Morris, Curly; Sherratt, Debbie; Flanagan, Louise; Gregory, Walter; Cavet, James
There is a significant unmet need in effective therapy for relapsed myeloma patients once they become refractory to bortezomib and lenalidomide. While data from the front line setting suggest bendamustine is superior to melphalan, there is no information defining optimal bendamustine dose in multiply-treated patients. We report a multi-centre randomized two-stage phase 2 trial simultaneously assessing deliverability and activity of two doses of bendamustine (60 mg/m2 vs. 100 mg/m2) days 1 and 8, thalidomide (100 mg) days 1-21 and low dose dexamethasone (20 mg) days 1, 8, 15 and 22 of a 28-d cycle. Ninety-four relapsing patients were treated on trial, with a median three prior treatment lines. A pre-planned interim deliverability and activity assessment led to closure of the 100 mg/m2 arm due to excess cytopenias, and led to amendment of entry criteria for cytopenias. Non-haematological toxicities including thromboembolism and neurotoxicity were infrequent. In the 60 mg/m2 arm, treatment was deliverable in 61.1% subjects and the partial response rate was 46.3% in the study eligible population, with 7.5 months progression-free survival. This study demonstrates bendamustine at 60 mg/m2 twice per month with thalidomide and dexamethasone is deliverable for repeated cycles in heavily pre-treated myeloma patients and has substantial clinical activity.
PMID: 25891006
ISSN: 1365-2141
CID: 3695122

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation

Brioli, A; Perrone, G; Patriarca, F; Pezzi, A; Nobile, F; Ballerini, F; Motta, M R; Ronconi, S; Tacchetti, P; Catalano, L; Zannetti, B A; Rizzi, S; Volpe, S; Zamagni, E; Liberati, A M; Mancuso, K; Boccadoro, M; Davies, F E; Morgan, G J; Palumbo, A; Cavo, M
Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34(+) cell yields as compared with TD (9.75 vs 10.76 × 10(6) CD34(+) cells/kg, P=0.220). For poor mobilizers (<4 × 10(6) CD34(+) cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P<0.0001; PFS: 16 vs 46%, P<0.0001; OS: 50 vs 80%, P<0.0001). These differences were retained across patients randomized to the TD arm; conversely, no differences in outcomes were seen in patients treated with VTD, irrespective of the number of harvested CD34(+) cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.
PMID: 25642764
ISSN: 1476-5365
CID: 3695082

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells [Letter]

Weinhold, Niels; Meissner, Tobias; Johnson, David C; Seckinger, Anja; Moreaux, Jérôme; Försti, Asta; Chen, Bowang; Nickel, Jolanta; Chubb, Daniel; Rawstron, Andrew C; Doughty, Chi; Dahir, Nasrin B; Begum, Dil B; Young, Kwee; Walker, Brian A; Hoffmann, Per; Nöthen, Marcus M; Davies, Faith E; Klein, Bernard; Goldschmidt, Hartmut; Morgan, Gareth J; Houlston, Richard S; Hose, Dirk; Hemminki, Kari
PMCID:4349291
PMID: 25480495
ISSN: 1592-8721
CID: 3648512

Enhancing cancer clonality analysis with integrative genomics

Peterson, Erich A; Bauer, Michael A; Chavan, Shweta S; Ashby, Cody; Weinhold, Niels; Heuck, Christoph J; Morgan, Gareth J; Johann, Donald J
INTRODUCTION/BACKGROUND:It is understood that cancer is a clonal disease initiated by a single cell, and that metastasis, which is the spread of cancer from the primary site, is also initiated by a single cell. The seemingly natural capability of cancer to adapt dynamically in a Darwinian manner is a primary reason for therapeutic failures. Survival advantages may be induced by cancer therapies and also occur as a result of inherent cell and microenvironmental factors. The selected "more fit" clones outmatch their competition and then become dominant in the tumor via propagation of progeny. This clonal expansion leads to relapse, therapeutic resistance and eventually death. The goal of this study is to develop and demonstrate a more detailed clonality approach by utilizing integrative genomics. METHODS:Patient tumor samples were profiled by Whole Exome Sequencing (WES) and RNA-seq on an Illumina HiSeq 2500 and methylation profiling was performed on the Illumina Infinium 450K array. STAR and the Haplotype Caller were used for RNA-seq processing. Custom approaches were used for the integration of the multi-omic datasets. RESULTS:Reported are major enhancements to CloneViz, which now provides capabilities enabling a formal tumor multi-dimensional clonality analysis by integrating: i) DNA mutations, ii) RNA expressed mutations, and iii) DNA methylation data. RNA and DNA methylation integration were not previously possible, by CloneViz (previous version) or any other clonality method to date. This new approach, named iCloneViz (integrated CloneViz) employs visualization and quantitative methods, revealing an integrative genomic mutational dissection and traceability (DNA, RNA, epigenetics) thru the different layers of molecular structures. CONCLUSION/CONCLUSIONS:The iCloneViz approach can be used for analysis of clonal evolution and mutational dynamics of multi-omic data sets. Revealing tumor clonal complexity in an integrative and quantitative manner facilitates improved mutational characterization, understanding, and therapeutic assignments.
PMCID:4597064
PMID: 26424171
ISSN: 1471-2105
CID: 3649572

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

Meißner, Tobias; Seckinger, Anja; Hemminki, Kari; Bertsch, Uta; Foersti, Asta; Haenel, Mathias; Duering, Jan; Salwender, Hans; Goldschmidt, Hartmut; Morgan, Gareth J; Hose, Dirk; Weinhold, Niels
BACKGROUND:Gene expression profiling (GEP) has significantly contributed to the elucidation of the molecular heterogeneity of multiple myeloma plasma cells (MMPC) and only recently it has been recommended for risk stratification. Prior to GEP MMPC need to be enriched resulting in an inability to immediately freeze bone marrow aspirates or use RNA stabilization reagents. As a result in multi-center MM trials sample processing delay due to shipping may be an important confounder of molecular analyses and risk stratification based on GEP data. RESULTS:We compared GEP data of 145 in-house and 246 shipped samples and detected 3301 down-regulated and 3501 up-regulated genes in shipped samples. For 3994 genes we confirmed differential expression in an independent set of 85 in-house and 97 shipped samples. Differentially expressed genes were enriched in processes like ribosome biogenesis, cell cycle, and apoptosis. Among GEP based risk predictors the IFM-15 seemed to underestimate high risk in shipped samples, whereas the GEP70 and the EMC-92 gene signatures were more robust. In order to provide a tool to assess the "shipping effect" in public repositories, we generated a 17-gene predictor for shipped samples with a 10-fold cross validation error rate of 0.06 for the training set and an error rate of 0.15 for the validation set. CONCLUSION/CONCLUSIONS:Sample processing delay significantly influences GEP of MMPC, implying it should be avoided if samples were used for risk stratification.
PMCID:4696100
PMID: 26714877
ISSN: 1755-8794
CID: 3648692

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Walker, Brian A; Boyle, Eileen M; Wardell, Christopher P; Murison, Alex; Begum, Dil B; Dahir, Nasrin M; Proszek, Paula Z; Johnson, David C; Kaiser, Martin F; Melchor, Lorenzo; Aronson, Lauren I; Scales, Matthew; Pawlyn, Charlotte; Mirabella, Fabio; Jones, John R; Brioli, Annamaria; Mikulasova, Aneta; Cairns, David A; Gregory, Walter M; Quartilho, Ana; Drayson, Mark T; Russell, Nigel; Cook, Gordon; Jackson, Graham H; Leleu, Xavier; Davies, Faith E; Morgan, Gareth J
PURPOSE/OBJECTIVE:At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe the pattern of tumor-acquired mutations, but their clinical relevance has yet to be established. METHODS:We performed whole-exome sequencing for 463 patients who presented with myeloma and were enrolled onto the National Cancer Research Institute Myeloma XI trial, for whom complete molecular cytogenetic and clinical outcome data were available. RESULTS:We identified 15 significantly mutated genes: IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, LTB, CYLD, and FGFR3. The mutational spectrum is dominated by mutations in the RAS (43%) and nuclear factor-κB (17%) pathways, but although they are prognostically neutral, they could be targeted therapeutically. Mutations in CCND1 and DNA repair pathway alterations (TP53, ATM, ATR, and ZNFHX4 mutations) are associated with a negative impact on survival. In contrast, those in IRF4 and EGR1 are associated with a favorable overall survival. We combined these novel mutation risk factors with the recurrent molecular adverse features and international staging system to generate an international staging system mutation score that can identify a high-risk population of patients who experience relapse and die prematurely. CONCLUSION/CONCLUSIONS:We have refined our understanding of genetic events in myeloma and identified clinically relevant mutations that may be used to better stratify patients at presentation.
PMID: 26282654
ISSN: 1527-7755
CID: 3648642

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Rawstron, Andy C; Gregory, Walter M; de Tute, Ruth M; Davies, Faith E; Bell, Sue E; Drayson, Mark T; Cook, Gordon; Jackson, Graham H; Morgan, Gareth J; Child, J Anthony; Owen, Roger G
The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for ≥10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111.
PMCID:4375716
PMID: 25645353
ISSN: 1528-0020
CID: 3648562

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis

Andersen, Jens Peter; Bøgsted, Martin; Dybkær, Karen; Mellqvist, Ulf-Henrik; Morgan, Gareth J; Goldschmidt, Hartmut; Dimopoulos, Meletios A; Einsele, Hermann; San Miguel, Jesús; Palumbo, Antonio; Sonneveld, Pieter; Johnsen, Hans Erik
BACKGROUND:International collaborative research is a mechanism for improving the development of disease-specific therapies and for improving health at the population level. However, limited data are available to assess the trends in research output related to orphan diseases. METHODS AND FINDINGS/RESULTS:We used bibliometric mapping and clustering methods to illustrate the level of fragmentation in myeloma research and the development of collaborative efforts. Publication data from Thomson Reuters Web of Science were retrieved for 2005-2009 and followed until 2013. We created a database of multiple myeloma publications, and we analysed impact and co-authorship density to identify scientific collaborations, developments, and international key players over time. The global annual publication volume for studies on multiple myeloma increased from 1,144 in 2005 to 1,628 in 2009, which represents a 43% increase. This increase is high compared to the 24% and 14% increases observed for lymphoma and leukaemia. The major proportion (>90% of publications) was from the US and EU over the study period. The output and impact in terms of citations, identified several successful groups with a large number of intra-cluster collaborations in the US and EU. The US-based myeloma clusters clearly stand out as the most productive and highly cited, and the European Myeloma Network members exhibited a doubling of collaborative publications from 2005 to 2009, still increasing up to 2013. CONCLUSION AND PERSPECTIVE/CONCLUSIONS:Multiple myeloma research output has increased substantially in the past decade. The fragmented European myeloma research activities based on national or regional groups are progressing, but they require a broad range of targeted research investments to improve multiple myeloma health care.
PMCID:4309532
PMID: 25629620
ISSN: 1932-6203
CID: 3648542

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Pawlyn, Charlotte; Melchor, Lorenzo; Murison, Alex; Wardell, Christopher P; Brioli, Annamaria; Boyle, Eileen M; Kaiser, Martin F; Walker, Brian A; Begum, Dil B; Dahir, Nasrin B; Proszek, Paula; Gregory, Walter M; Drayson, Mark T; Jackson, Graham H; Ross, Fiona M; Davies, Faith E; Morgan, Gareth J
The acquisition of the cytogenetic abnormalities hyperdiploidy or translocations into the immunoglobulin gene loci are considered as initiating events in the pathogenesis of myeloma and were often assumed to be mutually exclusive. These lesions have clinical significance; hyperdiploidy or the presence of the t(11;14) translocation is associated with a favorable outcome, whereas t(4;14), t(14;16), and t(14;20) are unfavorable. Poor outcomes are magnified when lesions occur in association with other high-risk features, del17p and +1q. Some patients have coexistence of both good and poor prognostic lesions, and there has been no consensus on their risk status. To address this, we have investigated their clinical impact using cases in the Myeloma IX study (ISRCTN68454111) and shown that the coexistence of hyperdiploidy or t(11;14) does not abrogate the poor prognosis associated with adverse molecular lesions, including translocations. We have also used single-cell analysis to study cases with coexistent translocations and hyperdiploidy to determine how these lesions cosegregate within the clonal substructure, and we have demonstrated that hyperdiploidy may precede IGH translocation in a proportion of patients. These findings have important clinical and biological implications, as we conclude patients with coexistence of adverse lesions and hyperdiploidy should be considered high risk and treated accordingly.
PMID: 25428216
ISSN: 1528-0020
CID: 3648502

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma

Mitchell, Jonathan S; Johnson, David C; Litchfield, Kevin; Broderick, Peter; Weinhold, Niels; Davies, Faith E; Gregory, Walter A; Jackson, Graham H; Kaiser, Martin; Morgan, Gareth J; Houlston, Richard S
A sizeable fraction of multiple myeloma (MM) is expected to be explained by heritable factors. Genome-wide association studies (GWAS) have successfully identified a number of common single-nucleotide polymorphisms (SNPs) influencing MM risk. While these SNPs only explain a small proportion of the genetic risk it is unclear how much is left to be detected by other, yet to be identified, common SNPs. Therefore, we applied Genome-Wide Complex Trait Analysis (GCTA) to 2,282 cases and 5,197 controls individuals to estimate the heritability of MM. We estimated that the heritability explained by known common MM risk SNPs identified in GWAS was 2.9% (± 2.4%), whereas the heritability explained by all common SNPs was 15.2% (± 2.8%). Comparing the heritability explained by the common variants with that from family studies, a fraction of the heritability may be explained by other genetic variants, such as rare variants. In summary, our results suggest that known MM SNPs only explain a small proportion of the heritability and more common SNPs remain to be identified.
PMCID:4513545
PMID: 26208354
ISSN: 2045-2322
CID: 3648632